6 days ago
AstraZeneca Says Its Automimmune Drug Reduced Disease Severity
AstraZeneca Plc 's experimental drug for a rare autoimmune disorder helped patients control their disease, the company said, boosting prospects for the potential blockbuster medicine.
The injectable drug gefurulimab for generalized myasthenia gravis showed a statistically significant and clinically meaningful reduction in disease severity while helping patients improve their ability to carry out daily tasks, AstraZeneca said in a statement.
